RR

Rajasekhar Reddy Ambati

Active Director Director DIN 08322632
DIN 08322632 First appointment Jan 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2019
Shareholding value •••• Premium profile

About Rajasekhar Reddy Ambati

Data last updated:

Rajasekhar Reddy Ambati is a Director at Scitex Pharmaceuticals Private Limited (since 2019). The company operates in Pharma. Scitex Pharmaceuticals Private Limited reported revenue of ₹8.31 Cr (FY 2024).

DIN 08322632
Primary Designation Director
Industry Pharma
First Appointment 07 Jan 2019
Oldest Company Age 7 yrs
Largest company Scitex Pharmaceuticals Private Limited · ₹8.31 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Jan 20192019₹8.31 Cr (FY 2024)Active

Board colleagues of Rajasekhar Reddy Ambati

Directorship timeline

Open interactive timeline →
Scitex Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rajasekhar Reddy Ambati

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajasekhar Reddy Ambati

Rajasekhar Reddy Ambati currently holds 1 directorship: Scitex Pharmaceuticals Private Limited (Director, since 07 Jan 2019, revenue ₹8.31 Cr (FY 2024)).

Rajasekhar Reddy Ambati was first appointed on 07 Jan 2019 as Director at Scitex Pharmaceuticals Private Limited.

The current boards of Rajasekhar Reddy Ambati's companies include Sri Charan Reddy Vemareddy (Scitex Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available